Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction.

P Lijnen, J Boelaert, P van Eeghem

    Clinical Nephrology
    |March 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Drievoudige Antihypertensive Behandeling.

    Acta clinica Belgica·2016
    Same author

    Feasibility of Adequate Thrombolytic Therapy with Streptokinase in Peripheral Arterial Occlusions: II. Changes in Peripheral Blood and Thrombolysis in vivo.

    British medical journal·2010
    Same author

    Independent double sided cardiac thrombosis causing simultaneous systemic and pulmonary embolism.

    European heart journal·1997
    Same author

    Power spectral analysis of RR interval and blood pressure short-term variability at rest and during dynamic exercise: comparison between cyclists and controls.

    International journal of sports medicine·1996
    Same author

    A consensus view on the technique of ambulatory blood pressure monitoring. The Fourth International Consensus Conference on 24-Hour Ambulatory Blood Pressure Monitoring.

    Hypertension (Dallas, Tex. : 1979)·1995
    Same author

    Prognostic value of training-induced change in peak exercise capacity in patients with myocardial infarcts and patients with coronary bypass surgery.

    The American journal of cardiology·1995
    Same journal

    Clinical characteristics and outcomes of adults with minimal change disease: A retrospective, cross-sectional study.

    Clinical nephrology·2026
    Same journal

    Analysis of end-stage renal disease mediated by cuproptosis-related genes.

    Clinical nephrology·2026
    Same journal

    The relationship between red cell distribution width and platelet ratio in acute kidney injury among ventilator-associated pneumonia patients: A MIMIC-IV database study.

    Clinical nephrology·2026
    Same journal

    Arterial stiffness and choroidal vascularity index in autosomal dominant polycystic kidney disease with preserved kidney function.

    Clinical nephrology·2026
    Same journal

    Antibody-drug conjugate therapy in a renal transplant patient with bladder cancer: A case report.

    Clinical nephrology·2026
    Same journal

    Epigenetic age enhances eGFR-based prediction of all-cause mortality: A cross-cohort validation of a novel risk model.

    Clinical nephrology·2026
    See all related articles

    Sulfinpyrazone use after myocardial infarction transiently impaired kidney function. This renal effect may stem from suppressed prostaglandin E2 and kallikrein synthesis, impacting kidney health post-MI.

    Area of Science:

    • Nephrology
    • Cardiology
    • Pharmacology

    Background:

    • Recent myocardial infarction (MI) poses significant cardiovascular risks.
    • Understanding drug effects on renal function post-MI is crucial for patient management.

    Purpose of the Study:

    • To investigate the impact of sulphinpyrazone on renal function in patients with recent myocardial infarction.
    • To explore the potential mechanisms behind any observed renal changes.

    Main Methods:

    • Randomized controlled trial involving 29 patients with recent MI.
    • Patients were allocated to either a placebo group (n=14) or a sulphinpyrazone group (n=15).
    • Sulfinpyrazone was administered at 4 x 200 mg daily for 7 days.

    Main Results:

    Related Experiment Videos

    • Transient and significant deterioration of renal function observed in the sulphinpyrazone group compared to placebo.
    • Suppression of 24-hour urinary prostaglandin E2 and kallikrein excretion in the sulphinpyrazone group.
    • Correlation between sulphinpyrazone administration and reduced renal function markers.

    Conclusions:

    • Sulfinpyrazone administration early after myocardial infarction can lead to a temporary decline in renal function.
    • The observed nephrotoxicity may be mediated by the inhibition of renal prostaglandin and kallikrein-kinin synthesis.
    • Further research is warranted to elucidate the long-term renal implications and optimal use of sulphinpyrazone in post-MI patients.